{"id":"NCT05403827","sponsor":"Kowa Research Institute, Inc.","briefTitle":"A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease","officialTitle":"A Phase 3, Prospective, Double-masked, Randomized, Multi-center, Vehicle-controlled, Parallel-group, 12-week Administration and 40-week Extension Study Confirming the Efficacy and Safety of K-161 Ophthalmic Solution for the Treatment of Moderate to Severe Dry Eye Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-07-03","primaryCompletion":"2023-08-25","completion":"2023-12-05","firstPosted":"2022-06-03","resultsPosted":"2025-01-14","lastUpdate":"2025-01-14"},"enrollment":644,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Disease"],"interventions":[{"type":"DRUG","name":"K-161","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"K-161","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy and safety of K-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.","primaryOutcome":{"measure":"Change in EDS (VAS) From Baseline to Day 85","timeFrame":"Baseline to Day 85","effectByArm":[{"arm":"K-161","deltaMin":-18,"sd":25.1},{"arm":"Vehicle","deltaMin":-19.4,"sd":25.34}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5019"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":51,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":321},"commonTop":["Instillation site pain"]}}